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Comparison of 68Ga‑DOTANOC 
with 18F‑FDG using PET/MRI 
imaging in patients with pulmonary 
tuberculosis
Claire M. Naftalin1, Francesca Leek2, James T. P. D. Hallinan1,3, Lih Kin Khor3, 
John J. Totman2, Jing Wang1, Yee Tang Wang4 & Nicholas I. Paton1,5*
We compared the somatostatin analog radioligand, DOTANOC, with FDG, to determine whether 
there was increased detection of active or sub‑clinical lesions in pulmonary tuberculosis (TB) with 
DOTANOC. Three groups were recruited: (1) active pulmonary TB; (2) IGRA‑positive household TB 
contacts; (3) pneumonia (non‑TB). DOTANOC PET/MRI followed by FDG PET/MRI was performed in 
active TB and pneumonia groups. TB contacts underwent FDG PET/MRI, then DOTANOC PET/MRI if 
abnormalities were detected. Quantitative and qualitative analyses were performed for total lung and 
individual lesions. Eight active TB participants, three TB contacts and three pneumonia patients had 
paired PET/MRI scans. In the active TB group, median  SUVmax[FDG] for parenchymal lesions was 7.69 
(range 3.00–15.88); median  SUVmax[DOTANOC] was 2.59 (1.48–6.40). Regions of tracer uptake were fairly 
similar for both radioligands, albeit more diffusely distributed in the FDG scans. In TB contacts, two 
PET/MRIs had parenchymal lesions detected with FDG (SUVmax 5.50 and 1.82), with corresponding 
DOTANOC uptake < 1. FDG and DOTANOC uptake was similar in pneumonia patients  (SUVmax[FDG] 
4.17–6.18;  SUVmax[DOTANOC] 2.92–4.78). DOTANOC can detect pulmonary TB lesions, but FDG is more 
sensitive for both active and sub‑clinical lesions. FDG remains the preferred ligand for clinical studies, 
although DOTANOC may provide additional value for pathogenesis studies.
Tuberculosis (TB) disease affects 10 million people worldwide every year, and is the leading cause of death from 
an infectious  disease1. New TB biomarkers are required for a variety of applications, including detection of sub-
clinical disease for early intervention to prevent disease progression; detection of new active TB cases; and for 
monitoring of treatment response in clinical practice or in clinical trials of new TB therapies.
Positron emission tomography (PET) imaging in combination with structural imaging may have value as a 
biomarker for detecting subclinical TB disease, active disease where the diagnosis is problematical, and an out-
come measure in clinical  trials2–7. The standard PET ligand, [18F]fluoro-2-deoxy-2-d-glucose (FDG), accumu-
lates in cells with high levels of glucose metabolism, and is a non-specific marker of inflammation. There may be 
additional value in using alternatives to FDG, if these have higher sensitivity or specificity for TB-infected  cells8.
Somatostatin analog PET radiotracers are useful in evaluating neuro-endocrine  tumours9–11 and other cancers’ 
 cells12–15 that have upregulated cell surface somatostatin receptors (SSTRs). These receptors are also overexpressed 
on activated  macrophages16,17, which are a key cell population infected by TB, residing within  granulomas18,19. 
Over-expression of somatostatin receptors in granulomas within lymph nodes of TB patients have been visual-
ised using in vitro  autoradiography20, and SSTR-positive cells have been detected using immunohistochemistry 
analysis in granulomas from multiple granulomatous  conditions21,22 including pulmonary nodules in  TB23.
In this study we compared PET in combination with magnetic resonance imaging (MRI) using the radi-
olabeled somatostatin analog 68Ga-DOTA-1-NaI3-octreotide (DOTANOC) with FDG to determine whether 
DOTANOC might increase the detection of active and sub-clinical TB lesions.
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Results
Participants. Eight participants with active TB, three TB contacts and three pneumonia patients underwent 
paired FDG and DOTANOC PET/MRI scans. One additional participant with active TB was enrolled, but PET 
imaging data was incomplete; seventeen additional contacts were enrolled but did not have lesions visible on the 
FDG scan and did not proceed to DOTANOC scanning. These participants are not reported further.
In the active TB group, there were six males, two females; median age of 37.5 years old (age range 22–61); five 
Chinese, two Malay, one Burmese. All patients had culture-confirmed drug-sensitive pulmonary TB (1 smear 
negative, 2 smear 2+, 2 smear 3+, 3 smear 4+). The median number of days on anti-tuberculous therapy at first 
scan was 18 days (range 8–29); all participants were taking standard combination therapy (rifampicin, isoniazid, 
ethambutol, pyrazinamide).
The three TB contacts were all female, aged 29–51 years old. Two participants were taking isoniazid TB 
prophylaxis (for 3 and 5 days prior to FDG scan). The three participants in the pneumonia group were male, aged 
between 36 and 73 years old. Diagnosis was clinical; patients had been taking antibiotic treatment for 2, 5 and 
6 days at the time of the FDG scan with a rapid response to antibiotic therapy. All participants were HIV negative.
DOTANOC PET/MRI and FDG PET/MRI analysis. In the active TB group, the median total percentage 
of disease-affected lung was 10.8% (range 1.6–30.0%) with FDG and 10.8% (range 1.6–30.6%) with DOTANOC. 
The median maximum standardized uptake value (SUVmax) of diseased lung parenchyma was 7.69 (range 3.00–
15.88) with FDG and 2.59 (range 1.48–6.40) with DOTANOC; median total lung  SUVmax[FDG]:SUVmax[DOTANOC] 
ratio was 2.60 (range 1.62–3.17). There was no significant correlation between total lung FDG:DOTANOC 
uptake ratio and time on TB treatment (rho = 0.14, p = 0.73). The distribution of disease was similar between FDG 
and DOTANOC scans but, in general, lesions appeared to be more diffuse with FDG, with clearer separation 
between adjacent lesions with DOTANOC (example in Fig. 1). A total of 33 individual lesions were identified 
in the eight patients (range 2–7 lesions per patient). Of the 22 lesions with both FDG and DOTANOC uptake, 
median individual lesion SUVmax [FDG]:SUVmax[DOTANOC] ratio was 2.23 (range 0.87–3.90). Nine parenchymal 
lesions (in five scans, range 1–3 lesions per scan) had FDG uptake (median SUVmax 2.15, range 1.64–2.94; vol-
ume 4.3 cm3, range 0.6–16.5 cm3) but no DOTANOC uptake (examples in Fig. 2). Conversely, there were only 
two parenchymal lesions (one in each of two patients) that had DOTANOC uptake (SUVmax 1.80 and 1.92; 
volume 0.4 cm3 and 0.6 cm3) but no uptake with FDG (Fig. 3). One additional lesion in a diffuse area adjacent 
to scar tissue had FDG uptake (FDG SUVmax 2.62; volume 43.4 cm3) but no DOTANOC uptake. Active hilar 
and/or mediastinal lymph nodes were seen in four scans, visible both with FDG (SUVmax range 1.20–2.75) and 
DOTANOC (SUVmax range 0.95–2.53).  
In the TB contacts, two FDG scans had parenchymal lesions: one in the anterior segment of the left upper 
lobe (SUVmax 5.50; volume 5.2 cm3; Fig. 4) and one in the anterior segment of the right upper lobe (FDG 
SUVmax 1.82; volume 0.7 cm3); the corresponding DOTANOC scans both had SUVmax < 1. Two FDG scans 
showed increased uptake in lymph nodes, one with SUVmax 8.12 (DOTANOC scan, SUVmax 1.25); and one 
with SUVmax 2.72 (no uptake on DOTANOC scan). The other two DOTANOC scans did not show any increased 
uptake in lymph nodes.
In the patients with pneumonia, large confluent areas of uptake were seen in all three scans with both FDG 
(SUVmax 4.17–6.18), and DOTANOC (SUVmax 2.92–4.78), with similar distribution in the two scans (example 
Figure 1.  Example of diffuse uptake of FDG (SUVmax 8.22) compared to DOTANOC uptake (SUVmax 2.96) 
which is more discrete. 55-year-old woman with pulmonary TB, smear 3+, on Day 8 of TB treatment.
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in Fig. 5). Two FDG scans showed increased uptake in lymph nodes, one with SUVmax 3.96 (no uptake on 
DOTANOC scan) and one with SUVmax 2.07 (DOTANOC SUVmax 1.27).
Discussion
Our study shows that PET scanning using a somatostatin analogue radioligand can detect pulmonary lesions in 
patients with active TB. This finding is consistent with a recent case report showing intense DOTANOC uptake 
in a single mesenteric tuberculous  lesion24, and several previous nuclear imaging studies using 99mTc- and 
111In-labelled somatostatin analogs, that have shown increased uptake in pathological lesions in TB and other 
granulomatous  diseases20,25–27. However, although we demonstrated that DOTANOC images TB lung disease, 
there does not appear to be any particular advantage over the standard ligand: the few discrepancies we observed 
in lesions visualised with the two ligands generally favoured FDG, and lesion uptake was, on average, more than 
two-fold higher with FDG for individual lesions and for total lung lesions. The two individual lesions visualised 
with DOTANOC, but not with FDG, were of low intensity and small volume.
Figure 2.  Lesions visualised with FDG but not DOTANOC in pulmonary TB (a) Lesions in right upper lobe 
visualised with FDG, largest volume 16.5 cm3, SUVmax 2.89. No uptake with DOTANOC. 22-year-old male, 
smear 2+, on TB treatment for 28 days. (b) Lesion in posterior basal segment of right lower lobe visualised with 
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The differences in lesion avidity we observed likely arise because the radioligands are detecting different 
aspects of TB-related pathology. Granulomas are rich in activated macrophages, but they also contain numerous 
other cell types including neutrophils, B-cells and T-cells. Furthermore, the cellular composition of individual 
granulomas varies, even within the same patient, and may evolve independently over time on TB  therapy28,29. 
FDG measures glucose uptake and labels a broad range of metabolically-active cells including neutrophils, 
the predominant cell type infected with replicating Mycobacterium tuberculosis during active pulmonary  TB30, 
and are present in lung tissue surrounding the  granulomas31. In contrast, DOTANOC measures somatostatin 
receptors which are upregulated on activated macrophages in granulomas, as well as  fibroblasts32,33, and B- 
and T-cells34; but not  neutrophils35. The small number of parenchymal lesions visualised more intensely with 
DOTANOC may have had greater density of macrophages and other somatostatin receptor cell types, but with 
lower metabolic activity, than the predominantly FDG-avid parenchymal lesions. The greater diversity of cell 
types that FDG labels may explain the relatively diffuse FDG uptake contrasting with more discrete lesions 
seen with DOTANOC. The greater avidity of lesions with FDG than DOTANOC is consistent with a study in 
a TB macaque model comparing FDG with 64Cu-LLP2A28, a ligand that binds to very late antigen-4 (VLA-4), 
expressed especially on epithelioid macrophages and T cells in granulomas. Lesion avidity was significantly higher 
Figure 3.  Lesions visualised with DOTANOC but not FDG in pulmonary TB (a) Lesion in right middle lobe 
visualised with DOTANOC, volume 0.6 cm3, SUVmax 1.92. No uptake with FDG. 55-year-old woman, smear 
3+, on Day 8 of TB treatment. (b) Lesion at apex right upper lobe visualised with DOTANOC, volume 0.4 cm3, 
SUVmax 1.80. No uptake with FDG. 57-year-old man, smear negative, on Day 11 of TB treatment.
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with FDG than 64Cu-LLP2A, particularly in early infection. The higher avidity seen with FDG than the compara-
tor cell receptor-specific ligand observed both in that study and our study could be due to differences in the cell 
types labelled within lesions, differences in ligand penetration into the lesions or, most likely, the large increase 
in glycolytic metabolism in the anaerobic centre of granulomas (labelled with FDG, but not DOTANOC)28.
In the macaque study, the difference between FDG and receptor-specific ligand was most evident within 
9 weeks of infection but diminished at later follow-up. In our study, considerations of radiation dose and patient 
acceptability limited us to performing one scan with each ligand, at a single time point. We studied TB patients 
relatively early during the course of treatment (within the first month) and it is possible that the relative lesion 
avidity detected with FDG and DOTANOC could change within each patient as treatment progresses. However, 
we also performed PET scans in household TB contacts, to determine whether DOTANOC could detect early 
Figure 4.  Lesion visualised in anterior segment of the left upper lobe adjacent to the aorta with FDG in 
47-year-old female, IGRA-positive TB contact, taking isoniazid for 5 days. FDG SUVmax 5.50. No DOTANOC 
uptake.
Figure 5.  Similar distribution of tracer uptake of DOTANOC and FDG in a 73-year old male patient with 
non-TB pneumonia. Lesion visualised in the left lower lobe mainly involving the superior segment.
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disease following TB exposure, as we had identified using FDG in an earlier  study36. The difference between 
FDG and DOTANOC in TB contacts was more marked than for patients with active TB: the parenchymal 
lesions seen on FDG were not visible with DOTANOC, and lymph node uptake on FDG was only visible in one 
of two DOTANOC scans. We cannot be certain whether the abnormalities seen in these contacts represent an 
early stage of active TB infection or whether they simply represent transient immune activity occurring early in 
 infection36. The finding of more prominent differences between ligands in early disease is again keeping with that 
seen in  macaques28. We included a group of patients with non-TB pneumonia as controls, to examine whether 
DOTANOC uptake might be specific for TB and therefore of potential diagnostic value in difficult-to-diagnose 
cases. However, we found clear uptake of DOTANOC in these pneumonia patients, with lesions similar in 
distribution to FDG, with only moderately reduced avidity. This is consistent with a few previous case reports 
of pneumonia detected as an incidental finding with SSTR  scintigraphy37–39, although not in all  reports40. In 
the case of non-TB pneumonia, DOTANOC may be labelling  fibroblasts32,33, B- and T-cell  lymphocytes34 and 
macrophages recruited to the lung in the later stages of pneumonia and which may express  SSTRs41. Although 
other non-mycobacterial causes of granulomatous pneumonia such as sarcoidosis and fungal infections were 
not ruled out, we can be confident that this was not TB (based on rapid resolution without TB treatment) and 
we do not need to know the precise identification of the pathogen to support the conclusion that DOTANOC is 
not specific for TB and has limited value for diagnostic purposes.
The main limitation of this study is the small sample size, although it was adequate for the intended descrip-
tive analysis. In patients with active TB, the DOTANOC scans were always performed 1–2 days after the FDG 
scan, but this delay could not explain the marked difference in uptake, given that abnormalities on PET scans 
of patients with TB are known to resolve only slowly on treatment, with residual activity detected even at or 
close to the end of  treatment5. In the contacts group, DOTANOC PET/MRI was only performed for TB con-
tacts with positive findings on the FDG scan (to minimise radiation exposure), so we cannot confidently rule 
out that DOTANOC may have detected lesions that FDG did not identify. However, this is unlikely given that 
DOTANOC appeared to be less sensitive than FDG for detecting individual lesions in active TB, or in the paired 
scans performed in contacts.
Our findings have a number of implications for future research. The lower avidity of lesions with DOTANOC 
suggest PET imaging using FDG is more suitable as an outcome parameter in TB clinical trials: the lower ampli-
tude of measurement using DOTANOC might reduce power to detect differences between treatment groups 
over time. Furthermore, FDG is manufactured more widely at lower cost and has lower radiation dose, and is 
therefore of more practical utility. Our findings that DOTANOC has substantial uptake in non-TB pneumonia 
also reduces any value in the differential diagnosis of lung lesions. However, our findings suggest there may be 
further research value in longitudinal studies with paired PET ligands labelling different cellular populations or 
metabolic processes. Changes in the relative uptake of ligands may provide important insights into the mecha-
nism of action of drugs or the host response in controlling TB. Further studies using radioligands labelling spe-
cific components of the mycobacteria such as Trehalose  analogues42, or targets of specific metabolism pathways 
such as  lipogenesis43, to differentiate between TB and other pathologies, may be a more productive direction for 
PET-based imaging research in TB.
In conclusion, we compared the somatostatin analog radioligand, DOTANOC, with the standard tracer, 
FDG, in detection of active pulmonary TB and sub-clinical pulmonary lesions. FDG was more sensitive than 
DOTANOC in detecting pulmonary TB lesions in both active and sub-clinical disease. DOTANOC uptake was 
not specific to TB lesions, showing comparable uptake to FDG in non-TB pneumonia. Future studies may identify 
promising TB imaging biomarkers by focusing on radioligands labelling specific targets of the mycobacteria, or 
pathways of TB metabolism.
Methods
We studied three groups of participants. The active TB group comprised adults with pulmonary TB (diagnosis 
based on compatible chest X-ray (CXR) findings with a positive acid-fast bacilli smear or positive GeneXpert 
test or TB-culture positive), who had started TB therapy within the previous one month. The TB contact group 
comprised close household contacts (sleeping in same house for ≥ 1 month before TB patient started therapy) 
of a smear-positive TB patient diagnosed within the last 2 months; were Interferon-Gamma Release Assay 
(IGRA) positive; had never received treatment for active TB disease; and had no clinical or X-ray evidence of 
pulmonary TB. The pneumonia group comprised adults with a clinical diagnosis of bacterial pneumonia with 
compatible CXR findings, who had shown a clinical response to antibiotic treatment started within the previous 
7 days. Common exclusion criteria for all groups included poorly-controlled diabetes, chronic kidney disease, 
malignancy requiring chemotherapy or radiotherapy, contraindication to radiation or MRI scanning, pregnancy 
or breast-feeding.
Participants had an HIV test and a standard posteroanterior CXR. The active TB group and pneumonia group 
underwent DOTANOC PET/MRI followed by FDG PET/MRI either 1 or 2 days later. The TB contact group 
underwent an initial FDG PET/MRI and if abnormalities were detected, this was followed by a DOTANOC 
PET/MRI between 1 and 7 days later.
The research received ethics approval from the National Healthcare Group’s Domain Specific Review Board 
in Singapore and regulatory approval was obtained from the Health Sciences Authority (HSA), Singapore. All 
research was performed in accordance with the relevant guidelines and regulations, and all participants provided 
written informed consent.
PET/MRI imaging protocol. All PET/MRI scans were performed at the National University of Singapore 
(NUS) Clinical Imaging Research Centre using a Siemens Biograph mMR PET/MR scanner (Siemens Health-
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14236  | https://doi.org/10.1038/s41598-020-71127-2
www.nature.com/scientificreports/
care, Erlangen, Germany). Prior to FDG PET/MRI, participants fasted for 6 h, following which an intravenous 
injection of 18F-FDG (mean activity 138.4 ± 9.4 MBq) was given to each participant. Fasting was not required 
prior to DOTANOC PET/MRI. An intravenous injection of 68Ga-DOTANOC (191.7 ± 9.3 MBq) was given. 
Scans for both radioligands were commenced immediately and data acquired up to 80 min post injection.
The PET images were reconstructed using Ordinary-Poisson Ordered-Subset Expectation–Maximisation 
(OP-OSEM) with 3 iterations and 21 subsets. A Gaussian post-smoothing filter of 6 mm full-width at half 
maximum (FWHM) was applied. The matrix size was 172 × 172, with a voxel size of 4.17 × 4.17 mm and slice 
thickness of 2.03 mm.
The MRI data was acquired using 12-channel body coils. Dixon images were collected for the purpose of 
MR-based Attenuation Correction (MRAC).
Imaging analysis. PET/MRI scans were evaluated and analysed by two independent radiologists; quan-
titative data was averaged, and any major discrepancies were agreed by consensus. Detailed analysis of each 
lesion was performed by a medical physicist. All evaluations were done blinded to clinical characteristics of the 
participants.
PET image analysis was performed on the reconstructed data acquired 60–70 min post injection, for both 
radioligands. Lung volumes were automatically segmented using ITK-SNAP44 on the MR navigated three-dimen-
sional sampling perfection with application optimized contrasts using different flip-angle evolutions (3D-SPACE) 
image acquired at the participant’s first visit. The volumes of interest (VOI) were automatically propagated to the 
PET  images45,46 and manually refined.
Any non-physiological uptake of FDG or DOTANOC in the lung above the mediastinal blood pool was 
considered  abnormal5,47,48. All voxels contained within the VOI with radioligand uptake above mediastinal 
blood pool were automatically thresholded using commercially available software (PMOD). The SUV for the 
mediastinal blood pool was obtained by positioning a 1 cm spherical VOI in the descending aorta. VOIs were 
removed from analysis upon consensus that increased uptake was due to artefact or vasculature.
Evaluation of scans was standardised using a structured case report form including quantitative measures 
and specific qualitative characteristics of tracer uptake within each lung.
This was a pilot study and sample size was determined pragmatically according to feasible numbers to allow 
descriptive comparison of imaging findings between the ligands in the three clinical populations.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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